Pfizer Received EC’s Conditional Marketing Authorization for Elerexfio for the Treatment of Relapsed and Refractory Multiple Myeloma
Shots:
- The EC has granted CMA based on cohort A of the P-II (MagnetisMM-3) study evaluating Elrexfio on patients (n=123) who received 3 prior therapies incl. an immunomodulatory agent, a proteasome inhibitor & an anti-CD38 Ab
- The result of the study showed an ORR of 61% with a 71% chance of sustaining the response at 15 mos. After 24 wks. of weekly therapy, the findings additionally supported Q2W dosing for all responding patients. After switching for at least 6 mos. before the data cut-off date (n = 50), 38% achieved CR, & 80% of patients maintained their response
- Elrexfio is bispecific antibody (BsAb) immunotherapy targeting BCMA and CD3. It binds to BCMA on myeloma cells and CD3 on T-cells, triggering T-cell activation to eliminate myeloma cells
Ref: Pfizer | Image: Pfizer
Related News:- Pfizer and BioNTech Reports P-I/II Study Result of mRNA-Based Combination Vaccine Program Against Influenza and COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
